{"schema_version":"secwatch.filing_event.v1","accession":"0001378325-26-000004","form_type":"8-K","ticker":"CV","cik":"0001378325","company_name":"CapsoVision, Inc","filed_at":"2026-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.950286+00:00","generated_at":"2026-05-15T09:28:15.293240+00:00","sec_items":["1.01","2.02","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CapsoVision closes $14M private placement; reports preliminary FY2025 revenue of $13.6M","bullets":["Raised $14M gross via 2.87M shares at $4.883 (5% discount to March 16 close); closed March 16, 2026.","Preliminary Q4 2025 revenue $3.9M; full-year 2025 revenue $13.6M; cash & equivalents ~$10.1M as of Dec. 31, 2025.","Abandoned first-gen CapsoCam Colon 510(k); prioritizing second-gen with improved imaging; pivotal study enrolling ~800 patients; over 500 enrolled; expects 510(k) submission in Q3 2026.","Breakthrough Device Designation for CapsoCam UGI denied in Jan 2026; plans to resubmit after ~90-patient study starting Q2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001378325-26-000004","json":"https://secwatch.observer/filing/0001378325-26-000004.json","markdown":"https://secwatch.observer/filing/0001378325-26-000004.md","text":"https://secwatch.observer/filing/0001378325-26-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1378325/000137832526000004/0001378325-26-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1378325/000137832526000004/cv-20260320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:28:15.293240+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a8fadfa5250d103a1e9bb68ffe7333f7bb8495dc","claim":"CapsoVision, Inc entered into Securities Purchase Agreement with selected accredited investors (the \"Investors\") valued at approximately $14 million (effective 2026-03-16).","evidence_excerpt":"On March 16, 2026, CapsoVision, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with selected accredited investors (the “Investors”), for the purposes of raising approximately $14 million in aggregate gross proceeds for the Company (the “Private Placement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1378325/000137832526000004/0001378325-26-000004-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"selected accredited investors (the \"Investors\")"},{"label":"Value","value":"approximately $14 million"},{"label":"Effective","value":"2026-03-16"}]},{"claim_id":"b9252fee21ce26d9f6dbc561a870b5c3c2386c30","claim":"CapsoVision, Inc entered into Registration Rights Agreement with the Investors (effective 2026-03-16).","evidence_excerpt":"In connection with the Private Placement, the Company entered into a registration rights agreement, dated March 16, 2026 (the “Registration Rights Agreement”), with the Investors, pursuant to which, among other things, the Company will (i) prepare and file with the Securities and Exchange Commission (the “SEC”) a registration statement to register for resale the Shares within 90 days after the closing of the Private Placement, and (ii) use commercially reasonable efforts to have such registration statement declared effective as soon as reasonably practicable following the filing thereof with the SEC.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1378325/000137832526000004/0001378325-26-000004-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the Investors"},{"label":"Effective","value":"2026-03-16"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}